Nicox: Positive results for NCX 470 in the Denali study

Nicox SA, an ophthalmology specialist, announced that NCX 470 demonstrated sustained efficacy for up to 12 months in the Phase 3 Denali clinical trial, with no new adverse events. Analyses confirmed robust intraocular pressure reduction, consistent with the Mont Blanc study. Regulatory filings for the United States and China are in preparation and are expected in the first half of 2026.

Denali, conducted on 696 patients, evaluated NCX 470 compared to latanoprost. The clinical program for Japan has begun, funded by Kowa. Nicox plans to present these results at ophthalmology conferences. The company, listed on Euronext Paris, plans to strategically expand into the American and Asian markets.